Ophthalmic Business News

In this episode, Steven D. Schwartz, MD, sits down with hosts, Jim Mazzo and John A. Hovanesian, MD, FACS, to discuss the advances and disappointments in retinal disease treatments, innovations in cataract surgery and more.

On one hand, the tax tactic described in this article applies only to a limited number of physicians: those who are in private practice and in practices that are taxed as S corporations.

In this episode I share my top 5 predictions in ophthalmology for 2022, including my thoughts on the future of COVID-19 and ocular gene therapy.

The passage of the Build Back Better Act by the Senate has been put on the back burner. But it makes sense for high-income earners and those with large retirement account balances to understand the provisions in the version of the bill passed by the U.S. House of Representatives in November 2021.

The Clareon family of IOLs is now available in the U.S., with an international rollout set to take place throughout 2022 and 2023, according to an Alcon press release.

In this episode, hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest news in eye care, then speak with Eric Rosenberg, DO, about the current state and future of digital ophthalmology.

Oculis and Accure Therapeutics have agreed to terms for Oculis to license ACT-01, which is under investigation for the prevention of damage to the optic nerve and retina, according to a press release.

What is unnecessary care? What does it look like in the real-world? Join White as he defines “medically unnecessary care” and shares a personal story.

The reality of health care practice in the 21st century is that lawsuits and liability lurk in the background for physicians.

“I’ve already had four pharmacy requests to change patients to ‘Fauxstasis,’ and it costs the same as Restasis!” This is from Jasmine, SkyVision’s insurance expert.